UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	November 1, 2017	
	Date of Report (Date of earliest event reported)	-
	NU SKIN ENTERPRISES, INC.	
	(Exact name of registrant as specified in its charter)	_
Delaware	001-12421	87-0565309
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
,	75 West Center Street Provo, Utah 84601	<u>_</u>
	(Address of principal executive offices and zip code)	
	(801) 345-1000	<u> </u>
	(Registrant's telephone number, including area code)	
	N/A	
	(Former name or former address, if changed since last report)	
Soliciting material pursuant to Pre-commencement communic	nant to Rule 425 under the Securities Act (17 CFR 230.425) Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) cations pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) cations pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))	
	registrant is an emerging growth company as defined in Rule 405 of the Securities ies Exchange Act of 1934 (§240.12b-2 of this chapter).	Act of 1933 (§230.405 of this
		Emerging growth company \Box
	cate by check mark if the registrant has elected not to use the extended transition parameters are provided pursuant to Section 13(a) of the Exchange Act. \Box	period for complying with any

Item 2.02 Results of Operations and Financial Condition.

On November 1, 2017, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the three- and nine-month periods ended September 30, 2017, and certain other information. A copy of the Company's press release is attached as Exhibit 99.1 to this report and incorporated by reference.

The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

The press release furnished herewith in Exhibit 99.1 may contain non-GAAP financial measures. Management believes non-GAAP financial measures assist management and investors in evaluating and comparing period-to-period results and projections in a more meaningful and consistent manner.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit.

99.1 Nu Skin Enterprises' press release dated November 1, 2017, regarding financial results for the three- and nine-month periods ended September 30, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC. (Registrant)

<u>/s/ Mark H. Lawrence</u> Mark H. Lawrence Chief Financial Officer

Date: November 1, 2017



FOR IMMEDIATE RELEASE

NU SKIN ENTERPRISES REPORTS THIRD-QUARTER 2017 RESULTS

PROVO, Utah — Nov. 1, 2017 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced third-quarter 2017 financial results.

Executive Summary

Revenue:	\$563.7 million, compared to \$604.2 million in Q3 2016, which included \$56 million in limited-time-offer (LTO) sales. Q3 2017 was negatively impacted approximately 1% by foreign currency fluctuations.
Earnings Per Share (EPS):	\$0.76, compared to \$0.98 in Q3 2016.
Sales Leaders:	64,200 – 5% year-over-year decrease, impacted by prior-year LTOs.
Customers:	1,069,000 – 7% year-over-year improvement.

"During the third quarter, we continued to execute our growth strategy and delivered results at the top-end of our previous guidance range," said Ritch Wood, chief executive officer. "We generated sequential improvements in the business, and are confident that our focus on social selling served as an important catalyst for steady customer and business growth in many of our markets. We also saw healthy energy within our sales force leading up to our October Nu Skin LIVE! event."

-more-

Q3 2017 Year-Over-Year Operating Results

Revenue:	\$563.7 million compared to \$604.2 million.
Gross Margin:	78.6% compared to 79.2%.
Selling Expenses:	41.7% of revenue compared to 42.3%.
G&A Expenses:	25.4% of revenue compared to 23.3%.
Operating Margin:	11.4% compared to 13.6%.
Other Income / (Expense):	(\$1.2) million compared to (\$5.7) million.
Income Tax Rate:	34.1% compared to 25.8% due to closing of Venezuela operations.
EPS:	\$0.76 compared to \$0.98.

Stockholder Value

Dividend Payments:	\$19.0 million.
Stock Repurchases:	\$25.7 million; \$152 million remaining in authorization.

2017 Outlook

Q4 Revenue:	\$650 to \$670 million; approximately 1% negative foreign currency impact.
Q4 EPS:	\$1.16 to \$1.21.
2017 Revenue:	\$2.263 to \$2.283 billion; approximately 3% growth.
2017 EPS	\$3.20 to \$3.25.

[&]quot;As we look ahead to the fourth quarter, we remain focused on expanding our customer base as we begin rolling out our platform, product and program initiatives," said Wood. "During our LIVE! event, we introduced several new products aimed at increasing the pace of our social selling efforts, including the ageLOC LumiSpa treatment and cleansing device which we plan to launch in every market during the first half of 2018. Over the next several quarters, we will begin implementing enhanced programs to more effectively reward our sales leaders and build long-term customer loyalty. We are confident that our strategic focus on these initiatives will help us build a solid base for future growth and enhanced value for our shareholders."

Nu Skin Enterprises, Inc. Nov. 1, 2017 Page 3

"Looking forward, we expect fourth-quarter revenue in the \$650 to \$670 million range which includes a one percent negative foreign currency impact," said Mark Lawrence, chief financial officer. "In the quarter, we continue to anticipate approximately \$100 million from the introduction of ageLOC LumiSpa, and project fourth-quarter earnings per share of \$1.16 to \$1.21."

Conference Call

The Nu Skin management team will host a conference call with the investment community on Nov. 1, at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available at the same URL through Nov. 15, 2017.

About Nu Skin Enterprises, Inc.

Founded more than 30 years ago, Nu Skin Enterprises, Inc. develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry's consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin is also traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskin.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, sales force and customer base, growth, initiatives and areas of focus, and new product introductions; projections regarding revenue, earnings per share, foreign currency fluctuations, and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

Nu Skin Enterprises, Inc. Nov. 1, 2017 Page 4

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- any failure of current or planned initiatives or products to generate interest among our sales force and customers and generate sponsoring and selling activities on a sustained basis;
- · risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
- · risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if we over-forecast demand for a product or change our planned initiatives or launch strategies;
- · regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- · adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- · unpredictable economic conditions and events globally;
- any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States and any adverse results of tax audits or favorable changes to tax laws in the company's various markets; and
- · continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue growth is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's revenue.

The Company's revenue results by segment for the three-month periods ended September 30 are presented in the following table (in thousands).

	2	2017	2016	% Change	Constant Currency % Change
Mainland China	\$	172,556	\$ 168,320	2.5%	2.5%
South Korea		89,238	136,188	(34.5%)	(33.7%)
Americas		79,214	71,250	11.2%	12.1%
South Asia/Pacific		78,994	70,867	11.5%	12.9%
Japan		62,513	72,489	(13.8%)	(6.5%)
Hong Kong/Taiwan		41,050	48,140	(14.7%)	(16.4%)
EMEA		40,133	 36,908	8.7%	3.2%
Total	\$	563,698	\$ 604,162	(6.7%)	(5.8%)

The Company's revenue results by segment for the nine-month periods ended September 30 are presented in the following table (in thousands).

		2017	 2016	% Change	Constant Currency % Change		
Mainland China	\$	494,658	\$ 471,319	5.0%	8.5%		
South Korea		258,626	315,342	(18.0%)	(19.5%)		
Americas		221,968	204,882	8.3%	9.1%		
South Asia/Pacific		216,727	226,742	(4.4%)	(2.9%)		
Japan		188,465	210,429	(10.4%)	(7.4%)		
Hong Kong/Taiwan		120,069	140,568	(14.6%)	(17.2%)		
EMEA	_	112,385	 107,186	4.9%	4.0%		
Total	\$	1,612,898	\$ 1,676,468	(3.8%)	(2.7%)		

The Company's Customers and Sales Leaders statistics by segment for the three-month periods ended September 30 are presented in the following table.

	20	17	20	16	% Increas	e (Decrease)
	Customers	Sales Leaders	Customers	Sales Leaders	Customers	Sales Leaders
Mainland China	190,000	25,600	182,000	25,300	4.4%	1.2%
South Korea	185,000	8,400	198,000	11,700	(6.6%)	(28.2%)
Americas	215,000	7,200	171,000	6,700	25.7%	7.5%
South Asia/Pacific	149,000	7,900	116,000	7,200	28.4%	9.7%
Japan	131,000	6,500	136,000	7,000	(3.7%)	(7.1%)
Hong Kong/Taiwan	71,000	4,300	75,000	5,300	(5.3%)	(18.9%)
EMEA	128,000	4,300	121,000	4,100	5.8%	4.9%
Total	1,069,000	64,200	999,000	67,300	7.0%	(4.6%)

[&]quot;Customers" are persons who purchased products directly from the company during the previous three months.

[&]quot;Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited) For the Third Quarters Ended September 30, 2017 and 2016 (in thousands, except per share amounts)

	2017		2016	
Revenue	\$	563,698	\$	604,162
Cost of sales		120,832		125,863
Gross profit		442,866		478,299
Operating expenses: Selling expenses General and administrative expenses Total operating expenses		235,285 143,219 378,504	_	255,274 140,651 395,925
Operating income		64,362		82,374
Other income (expense), net Income before provision for income taxes Provision for income taxes		(1,172) 63,190 21,518		(5,695) 76,679 19,807
Net income	\$	41,672	\$	56,872
Net income per share: Basic Diluted	\$ \$	0.79 0.76	\$ \$	1.02 0.98
Weighted average common shares outstanding: Basic Diluted		52,873 54,834		55,983 57,852
-more-				

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited) For the Nine-Month Periods Ended September 30, 2017 and 2016 (in thousands, except per share amounts)

		2017		2016
Revenue	\$	1,612,898	\$	1,676,468
Cost of sales		353,619		391,937
Gross profit		1,259,279		1,284,531
Operating expenses: Selling expenses General and administrative expenses Total operating expenses		672,646 411,270 1,083,916		699,196 415,014 1,114,210
Operating income		175,363		170,321
Other income (expense), net Income before provision for income taxes Provision for income taxes		(8,470) 166,893 55,691	_	(19,618) 150,703 45,802
Net income	\$	111,202	\$	104,901
Net income per share: Basic Diluted Weighted average common shares outstanding: Basic Basic	\$ \$	2.10 2.04 52,834	\$ \$	1.87 1.85
Diluted		54,519		56,586

-more-

NU SKIN ENTERPRISES, INC. **Consolidated Balance Sheets (Unaudited)**

(in thousands)

	September 30, 2017		December 31, 2016	
ASSETS				
Current assets:				
Cash and cash equivalents	\$	363,769	\$	357,246
Current investments		7,983		10,880
Accounts receivable		37,725		31,199
Inventories, net		252,470		249,936
Prepaid expenses and other		87,282		65,076
		749,229		714,337
Property and equipment, net		449,555		444,732
Goodwill		114,954		114,954
Other intangible assets, net		68,904		63,553
Other assets		164,689		136,469
Total assets	\$	1,547,331	\$	1,474,045
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable	\$	41,638	\$	41,261
Accrued expenses		276,486		275,023
Current portion of long-term debt		101,701		82,727
		419,825		399,011
Long-term debt		316,519		334,165
Other liabilities		93,464		76,799
Total liabilities		829,808		809,975
Stockholders' equity:				
Class A common stock		91		91
Additional paid-in capital		460,782		439,635
Treasury stock, at cost		(1,284,043)		(1,250,123)
Accumulated other comprehensive loss		(69,233)		(84,122)
Retained earnings		1,609,926		1,558,589
		717,523		664,070
Total liabilities and stockholders' equity	\$	1,547,331	\$	1,474,045

###

Nu Skin Social Media Channels

CONTACTS:

Media: media@nuskin.com, (801) 345-6397

Investors: investorrelations@nuskin.com, (801) 345-3577